ARTICLE | Clinical News
AVP-21D9 regulatory update
November 15, 2010 8:00 AM UTC
FDA granted Orphan Drug designation for Emergent's AVP-21D9 to treat inhalation anthrax. The human mAb against Bacillus anthracis protective antigen, which is being developed under FDA's Animal Rule,...